Search:
Computing and Library Services - delivering an inspiring information environment

The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs relapse prevention in addiction. Part A: Study description

Paterson, Louise M., Flechais, Remy S. A., Murphy, Anna, Reed, Laurence J., Abbott, Sanja, Boyapati, Venkataramana, Elliott, Rebecca, Erritzoe, David, Ersche, Karen D., Faluyi, Yetunde, Faravelli, Luca, Fernandez-Egea, Emilio, Kalk, Nicola J., Kuchibatla, Shankar S., McGonigle, John, Metastasio, Antonio, Mick, Inge, Nestor, Liam, Orban, Csaba, Passetti, Filippo, Rabiner, Eugenii A., Smith, Dana G., Suckling, John, Tait, Roger, Taylor, Eleanor M., Waldman, Adam D., Robbins, Trevor W., Deakin, J. F. William, Nutt, David J. and Lingford-Hughes, Anne R. (2015) The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs relapse prevention in addiction. Part A: Study description. Journal of Psychopharmacology, 29 (9). pp. 943-960. ISSN 0269-8811

Metadata only available from this repository.

Abstract

Drug and alcohol dependence are global problems with substantial societal costs. There are few treatments for relapse prevention and therefore a pressing need for further study of brain mechanisms underpinning relapse circuitry. The Imperial College Cambridge Manchester (ICCAM) platform study is an experimental medicine approach to this problem: using functional magnetic resonance imaging (fMRI) techniques and selective pharmacological tools, it aims to explore the neuropharmacology of putative relapse pathways in cocaine, alcohol, opiate dependent, and healthy individuals to inform future drug development. Addiction studies typically involve small samples because of recruitment difficulties and attrition. We established the platform in three centres to assess the feasibility of a multisite approach to address these issues. Pharmacological modulation of reward, impulsivity and emotional reactivity were investigated in a monetary incentive delay task, an inhibitory control task, and an evocative images task, using selective antagonists for µ-opioid, dopamine D3 receptor (DRD3) and neurokinin 1 (NK1) receptors (naltrexone, GSK598809, vofopitant/aprepitant), in a placebo-controlled, randomised, crossover design. In two years, 609 scans were performed, with 155 individuals scanned at baseline. Attrition was low and the majority of individuals were sufficiently motivated to complete all five sessions (n=87). We describe herein the study design, main aims, recruitment numbers, sample characteristics, and explain the test hypotheses and anticipated study outputs.

Item Type: Article
Uncontrolled Keywords: Addiction, functional magnetic resonance imaging, µ-opioid receptor, neurokinin 1 receptor
Subjects: R Medicine > RM Therapeutics. Pharmacology
Schools: School of Applied Sciences
Related URLs:
Depositing User: Jonathan Cook
Date Deposited: 14 Aug 2017 14:53
Last Modified: 14 Aug 2017 14:53
URI: http://eprints.hud.ac.uk/id/eprint/32815

Downloads

Downloads per month over past year

Repository Staff Only: item control page

View Item View Item

University of Huddersfield, Queensgate, Huddersfield, HD1 3DH Copyright and Disclaimer All rights reserved ©